SAN JOSE, CALIF — VS3 Medical, Inc , a private company developing novel neurovascular implants, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its VS3 System. The designation is based on evidence demonstrating that the system has the potential to resolve debilitating pulsatile tinnitus due to venous sinus stenosis....
Continue reading at Hearing Tracker
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — the VS3 System has received FDA Breakthrough Device Designation but is not yet approved or commercially available; audiologists should monitor future trial and approval outcomes.
If successfully developed and approved, a neurovascular implant specifically targeting pulsatile tinnitus would represent a novel treatment pathway for a condition that currently has very limited evidence-based interventions.
- 01VS3 Medical's VS3 System received FDA Breakthrough Device Designation for pulsatile tinnitus.
- 02The designation accelerates FDA review but does not constitute approval or market clearance.
- 03The VS3 System is a neurovascular implant — a device placed near blood vessels in the head/neck area.
- 04Pulsatile tinnitus is a relatively rare form of tinnitus with few established treatments.
- 05This is an early-stage regulatory milestone; clinical efficacy and safety data are not yet publicly available.
The FDA granted Breakthrough Device Designation to the VS3 System for the treatment of pulsatile tinnitus.
press releasesupportedThe VS3 System is a neurovascular implant intended to treat pulsatile tinnitus.
press releaseunclear